SSSeftika Sari

Seftika Sari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seftika Sari has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analysis of Cold Chain Product Management in Community Health Centers in Siak Regency Based on Their Accreditation Level

    by Monica Rifa Putri, Husnawati Husnawati, Seftika Sari

    This study aims to analyze the management of cold chain products in primary health centers (Puskesmas) across Siak Regency based on their accreditation levels. The research is motivated by the high rate of cold chain management deviations that may compromise the quality and effectiveness of medicines, particularly vaccines. A mixed-method approach with a sequential explanatory model was applied, involving all 16 Puskesmas as the total sample. Quantitative data were collected through observations using the 2020 CDOB checklist, while qualitative data were obtained from in-depth interviews with cold chain officers. Data analysis employed the Chi-Square test to examine the relationship between accreditation levels and cold chain management quality. The results revealed a significant relationship between accreditation status and management quality, especially in facility compliance, SOP adherence, maintenance, and calibration standards. Highly accredited Puskesmas (paripurna and utama) demonstrated “good” to “very good” management performance, whereas non-accredited facilities remained in the “fair” category or lower. These findings highlight accreditation as a key determinant of effective cold chain management. The study underscores the need for continuous training, improved infrastructure, and enhanced monitoring systems to ensure the quality of cold chain medicines in primary health services.

  • Open Access

    Health Related Quality of Life (HRQoL) in Type 2 Diabetes Mellitus Patients Based on Antidiabetic Prescription Patterns

    by Seftika Sari, Erniza Pratiwi, Dinda Farahdilla, Mt Ghozali, Indriyati Hadi Sulistyaningrum, Prasojo Pribadi

    Health Related Quality of Life (HRQoL) in Type 2 Diabetes Mellitus Patients Based on Antidiabetic Prescription Patterns

  • Open Access

    Analisis Tantangan Dan Solusi Manajemen Rantai Dingin Penyimpanan Obat Di Puskesmas: Kajian Literatur

    by Monica Rifa Putri, Seftika Sari, Neni Frimayanti

    Penyimpanan obat dengan sistem rantai dingin di fasilitas kesehatan primer, seperti puskesmas, merupakan elemen krusial untuk menjaga efektivitas obat, terutama vaksin dan obat biologis. Penelitian ini bertujuan untuk menganalisis tantangan yang dihadapi dalam manajemen rantai dingin di puskesmas serta memberikan solusi yang efektif. Metode yang digunakan adalah tinjauan literatur dari berbagai sumber akademik yang relevan, dengan fokus pada artikel yang diterbitkan antara tahun 2020 hingga 2024. Penelitian ini menemukan bahwa tantangan utama dalam pengelolaan rantai dingin meliputi ketidaksesuaian suhu, keterbatasan infrastruktur, dan kurangnya pelatihan bagi tenaga kesehatan. Berdasarkan temuan ini, solusi yang disarankan termasuk penerapan teknologi pemantauan suhu berbasis Internet of Things (IoT), peningkatan pelatihan bagi petugas kesehatan, serta perbaikan infrastruktur penyimpanan. Implikasi dari penelitian ini menunjukkan bahwa manajemen rantai dingin yang efektif memerlukan pendekatan yang komprehensif dengan kolaborasi antara berbagai pemangku kepentingan, termasuk pemerintah dan masyarakat, untuk memastikan kualitas dan keamanan obat yang disimpan, yang pada gilirannya mendukung keberhasilan program imunisasi dan kesehatan masyarakat.

  • Open Access

    Cost of illness pasien gagal ginjal kronis di Rumah Sakit Umum Daerah Arifin Achmad Provinsi Riau

    by Seftika Sari, Zikra Suhada, Tiara Triagustini

    Intisari Latar belakang: Meningkatnya frekuensi gagal ginjal kronik menimbulkan masalah kesehatan yang signifikan di seluruh dunia. Pasien gagal ginjal kronik mengalami peningkatan angka kesakitan dan kematian. Sejumlah besar orang yang menderita gagal ginjal kronis mengalami infeksi pada tahap akhir penyakitnya, sehingga menyebabkan pengobatan yang tidak efisien, tekanan keuangan yang besar, dan dampak negatif yang patut dicatat terhadap emosi, keuangan, dan kesejahteraan umum mereka.Metode: Penelitian ini merupakan penelitian farmakoekonomi menggunakan perspektif provider dan societal dengan desain deskriptif observasional. Sampel penelitian ini berjumlah 75 orang melalui non-random sampling dengan menggunakan purposive sampling.Hasil: Berdasarkan hasil penelitian, total rata-rata biaya pengobatan pasien gagal ginjal kronis adalah Rp. 5.118.274,72. Total biaya terbesar adalah biaya pengobatan langsung (44,46%). Adapun biaya pengobatan tidak langsung sebesar 23,54% dan biaya hilangnya produktivitas senilai 32%.Kesimpulan: Biaya rata-rata terapi total yaitu sebesar Rp. 5.118.274,7; dan karakteristik pasien yang memiliki hubungan terhadap biaya terapi yaitu derajat keparhan p-value 0,019 dan lama penyakit p-value 0,033.Kata kunci: Gagal ginjal kronis, cost of Illness, farmakoekonomi


  • Open Access

    Adaptation and validation of the telepharmacy service adoption behavior questionnaire during the COVID-19 pandemic crisis

    by Indriyati Hadi Sulistyaningrum, Prasojo Pribadi, Seftika Sari

    Telepharmacy is an online application used to provide pharmaceutical services in the modern era. Therefore, this study aims to develop a questionnaire on a research model that integrates three well-known theories, namely the unified theory of acceptance and use of technology (UTAUT), the protection motivation theory (PMT), and the DeLone and McLean information success model, to determine factors that influence people’s behavior towards the adoption of telepharmacy services. A cross-sectional observational method was used with the purposive sampling technique. A total of 118 participants who were at least 18 years old received the questionnaire. They were selected using convenience sampling from a variety of population groupings. Data analysis was then performed with the exploratory factor analysis (EFA). Factor extraction was carried out using principal component analysis and varimax rotation. The results show 8 factors consisting of social influence and support 15.54%; understanding of proficiency, confidence and quality of information 11.06%; condition of facilities and skills 6.64%; severity and suffering 7.87%; time opportunity support and system quality 7.74%; intention to adopt telepharmacy 7.34%; perceived vulnerability 6.80%; and attitude 6.37%. Furthermore, the overall construct formed can explain 72.40% of the total variance. These results indicate that the telepharmacy service adoption behavior questionnaire is valid and reliable.


  • Open Access

    HEALTH-RELATED QUALITY OF LIFE POST-SINOVAC VACCINE IN COMMUNITIES IN TAMPAN DISTRICT AND MARPOYAN DISTRICT, PEKANBARU CITY

    by Seftika Sari, Rickha Octavia, Novelia Sukista

    Giving the Sinovac vaccine for Covid 19 can cause several side effects. The existence of side effects that occur, of course, affect their lives, including a decrease in activity, productivity and quality of life. This study aims to determine the HRQoL score in the community after the Sinovac vaccine in Tampan District and Marpoyan District, Pekanbaru City. The research method is analytic observational with a cross-sectional design. The research sample was people who received the first vaccine recorded at the Puskesmas in Tampan District and Marpoyan District, Pekanbaru City, which was selected by purposive sampling technique according to inclusion and exclusion criteria and obtained a sample of 100 respondents. The instrument is a questionnaire EQ5D5L and EQ-VAS. The study results showed that there was little problem with the dimensions of pain (37%) and usual activities (14%), with a score of 0,944 (EQ5D5L) and 0,975 (EQ-VAS). In conclusion, the HRQoL scores on EQ5D5L and EQ-VAS are close to 1, which means close to perfect. This research is expected to be a reference for stakeholders in selecting preventive therapy for Covid 19 and can be used as initial data for cost-utility analysis research.

  • Open Access

    Effectiveness of Oxalis corniculata L. Ethanol Extract against Mono-Species of Biofilm Staphylococcus aureus

    by Hasyrul Hamzah, Khalish Arsy Al Khairy Siregar, Ari Nurwijayanto, Retno Wahyuningrum, Seftika Sari

    Inappropriate administration of antibiotics can cause resistance to bacteria. Staphylococcus aureus is one of the strong biofilm-forming bacteria that cause antibiotic resistance. Calincing (Oxalis corniculata L.) leaves have excellent antibacterial activity, but their antibiofilm activity against S. aureus has not been reported until now. Currently, the discovery of new antibiofilm against S. aureus biofilms is significant to prevent the impact of infections caused by biofilms. This study was intended to determine the effectiveness of the ethanol extract of O. corniculata leaves in inhibiting and eradicating S. aureus biofilm formation. Planktonic testing, inhibition, and biofilm eradication activity were carried out using the microtiter broth method. Antibiofilm activity of O. corniculata leaves against S. aureus biofilm was analyzed by calculating the minimum concentration of biofilm inhibitor (MBIC50) and minimum biofilm eradication concentration (MBEC50). Data were analyzed using the Statistical Package for the Social Sciences (SPSS) with a 95% confidence level. Oxalis corniculata leaves showed inhibitory activity on the formation of the tested S. aureus biofilm. The ethanol extract of 1% O. corniculata leaves gave 76.23±0.01% antibacterial activity of S. aureus and 71.32±0.01% of mid-phase antibiofilm activity, and 69.33±0.01% maturation phase. The results also prove that the ethanolic extract of O. corniculata leaves can eradicate S. aureus biofilm formation. Therefore, the ethanol extract of O. corniculata leaves can be developed as a new antibiofilm against S. aureus.


  • Open Access

    Efikasi Afatinib dan Gefitinib pada Pasien Non-small Cell Lung Cancer EGFR Mutasi Positif: Tinjauan Sistematis

    by Seftika Sari, Tri M. Andayani, Dwi Endarti, Kartika Widayati

    Efikasi Afatinib dan Gefitinib pada Pasien Non-small Cell Lung Cancer EGFR Mutasi Positif: Tinjauan Sistematis


  • Open Access

    Health-related quality of life in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation with tyrosine kinase inhibitors treatment: a systematic review

    by Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati

    Tyrosine Kinase Inhibitors (TKIs) have been recommended by the National Comprehensive Cancer Network (NCCN) as first-line therapy in Non-Small Cell Lung Cancer (NSCLC) patients with EGFR mutations. In addition to prolonging Progression-Free Survival and Overall Survival, one of the treatment goals also considers improving the health-related quality of life (HRQOL), which can help to achieve the patients' treatment targets. Several systematic review studies related to HRQOL in advanced NSCLC patients have already been carried out, but there are only a few studies of HRQOL in NSCLC patients who experience EGFR mutations and are treated with TKIs in their specific treatment. This Systematic review aims to provide an overview of the impact of TKIs on HRQOL. Relevant studies were identified from Science Direct, PubMed, and Scopus. They were limited to articles explaining TKIs as first-line therapy, written in English, not a systematic review or meta-analysis, and not containing incomplete text. Electronic data-based search produced 112 articles, with 21 articles matched the title and abstract, yet only nine articles met the inclusion and exclusion to be reviewed. In general, the impact of HRQOL on TKIs is better than platinum and placebo-based chemotherapy. Afatinib, erlotinib, and gefitinib further improved HRQOL compared to platinum and placebo-based chemotherapy seen from the improvements in symptoms, physical function, and social function scale. However, gefitinib vs erlotinib showed no significant difference in patients’ the quality of life. TKIs provide better HRQOL than platinum and placebo-based chemotherapy.